Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
46
RYTM Quote, Financials, Valuation and Earnings
Last price:
$55.81
Seasonality move
:
-14.94%
Day range:
$55.34 - $56.31
52-week range:
$35.17 - $68.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
29.98x
P/B ratio:
306.05x
Volume:
194.7K
Avg. volume:
563.3K
1-year change:
20.5%
Market cap:
$3.4B
Revenue:
$77.4M
EPS (TTM):
-$4.33
Analysts' Opinion
-
Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $72.82, Rhythm Pharmaceuticals has an estimated upside of 30.38% from its current price of $55.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $58.00 representing -3.85% downside risk from its current price of $55.85.
Fair Value
-
According to the consensus of 7 analysts, Rhythm Pharmaceuticals has 30.38% upside to fair value with a price target of $72.82 per share.
RYTM vs. S&P 500
-
Over the past 5 trading days, Rhythm Pharmaceuticals has underperformed the S&P 500 by -4.49% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Rhythm Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rhythm Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Rhythm Pharmaceuticals reported revenues of $33.3M.
Earnings Growth
-
Rhythm Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Rhythm Pharmaceuticals reported earnings per share of -$0.73.
Enterprise value:
3.1B
EV / Invested capital:
279.45x
Price / LTM sales:
29.98x
EV / EBIT:
--
EV / Revenue:
27.85x
PEG ratio (5yr expected):
-0.39x
EV / Free cash flow:
-25.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$99.7M
Return On Assets:
-76.55%
Net Income Margin (TTM):
-230.08%
Return On Equity:
-208.96%
Return On Invested Capital:
-208.96%
Operating Margin:
-131.98%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $16.7M | $62M | $112.5M | $22.5M | $33.3M | |
| Gross Profit | $15.3M | $54.9M | $99.7M | $20.1M | $29.4M | |
| Operating Income | -$188M | -$185.2M | -$265.5M | -$44M | -$43.9M | |
| EBITDA | -$185.7M | -$170.9M | -$237.5M | -$40.2M | -$38.4M | |
| Diluted EPS | -$3.58 | -$3.25 | -$4.33 | -$0.76 | -$0.73 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $209.9M | $335.6M | $361.9M | $329.2M | $340.3M | |
| Total Assets | $215.5M | $355.8M | $389.6M | $354.2M | $363.6M | |
| Current Liabilities | $15.8M | $23.5M | $33.1M | $50.1M | $97.6M | |
| Total Liabilities | $18.5M | $33.6M | $108.4M | $156.7M | $352.4M | |
| Total Equity | $196.9M | $322.3M | $281.2M | $197.5M | $11.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$179.9M | -$140.8M | -$124.4M | -$29.3M | -$25.2M | |
| Cash From Investing | $76.1M | -$69.1M | -$46.7M | -$95M | -$90.8M | |
| Cash From Financing | $196.6M | $89.3M | $155.3M | $73M | $2.5M | |
| Free Cash Flow | -$184.3M | -$140.8M | -$124.4M | -$23.9M | $14.8M | |
RYTM
Sector
Market Cap
$3.4B
$46.1M
Price % of 52-Week High
81.44%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
20.5%
-30.52%
Beta (5-Year)
2.141
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$55.56
200-day SMA
Buy
Level
$47.04
Bollinger Bands (100)
Buy
Level
46.59 - 58.07
Chaikin Money Flow
Buy
Level
54.2M
20-day SMA
Sell
Level
$57.84
Relative Strength Index (RSI14)
Sell
Level
46.14
ADX Line
Buy
Level
8.32
Williams %R
Neutral
Level
-66.0455
50-day SMA
Sell
Level
$56.36
MACD (12, 26)
Sell
Level
-0.60
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
114.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.7493)
Sell
CA Score
(Annual)
Level (-2.036)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.2469)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Stock Forecast FAQ
In the current month, RYTM has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RYTM average analyst price target in the past 3 months is $72.82.
-
Where Will Rhythm Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rhythm Pharmaceuticals share price will rise to $72.82 per share over the next 12 months.
-
What Do Analysts Say About Rhythm Pharmaceuticals?
Analysts are divided on their view about Rhythm Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rhythm Pharmaceuticals is a Sell and believe this share price will drop from its current level to $58.00.
-
What Is Rhythm Pharmaceuticals's Price Target?
The price target for Rhythm Pharmaceuticals over the next 1-year time period is forecast to be $72.82 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RYTM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rhythm Pharmaceuticals is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RYTM?
You can purchase shares of Rhythm Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rhythm Pharmaceuticals shares.
-
What Is The Rhythm Pharmaceuticals Share Price Today?
Rhythm Pharmaceuticals was last trading at $55.81 per share. This represents the most recent stock quote for Rhythm Pharmaceuticals. Yesterday, Rhythm Pharmaceuticals closed at $55.85 per share.
-
How To Buy Rhythm Pharmaceuticals Stock Online?
In order to purchase Rhythm Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
